Tracey L Weissgerber1, Augustine Rajakumar, Ashley C Myerski, Lia R Edmunds, Robert W Powers, James M Roberts, Robin E Gandley, Carl A Hubel. 1. Division of Nephrology and Hypertension (T.L.W.), Mayo Clinic, Rochester, Minnesota 55905; Beth Israel Deaconess Medical Center (A.R.), Boston, Massachusetts 02215; Magee-Womens Research Institute (A.C.M., L.R.E., R.W.P., J.M.R., R.E.G., C.A.H.), and Department of Obstetrics, Gynecology, and Reproductive Sciences (R.W.P., J.M.R., C.A.H.), University of Pittsburgh, Pittsburgh, Pennsylvania 15213; Department of Environmental and Occupational Health (R.E.G., C.A.H.), and Department of Epidemiology (J.M.R.), Graduate School of Public Health (J.M.R.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261; and Clinical and Translational Science Institute (J.M.R.), University of Pittsburgh, Pittsburgh, Pennsylvania 15260.
Abstract
CONTEXT: Research examining the source of excess soluble fms-like tyrosine kinase 1 (sFLT1) in preeclampsia has focused on the placenta. The potential contribution of the releasable store of sFLT1 in the systemic vasculature is unknown. OBJECTIVE: We asked whether the nonplacental releasable store of sFLT1 is larger in women with previous preeclampsia than in women with a previous uncomplicated pregnancy. DESIGN: We administered heparin to nulligravid women and to women with previous preeclampsia or a previous uncomplicated pregnancy. We compared post-heparin sFLT1 concentrations with those observed in uncomplicated pregnancy and preeclampsia. SETTING: The study was performed at Magee-Womens Hospital. PATIENTS: Participants included nulligravidas (n = 8), women 6-24 months postpartum (previous uncomplicated pregnancy, n = 16; previous preeclampsia, n = 15), and pregnant women (uncomplicated pregnancy, n = 30; preeclampsia, n = 25). INTERVENTION: Nonpregnant women received an unfractionated heparin bolus. MAIN OUTCOME MEASURES: Pre- and post-heparin plasma sFLT1, placental growth factor, and vascular endothelial growth factor were measured. RESULTS: In nonpregnant women, heparin increased plasma sFLT1 by 250-fold (P < .01), increased placental growth factor by 7-fold (P < .01), and decreased free vascular endothelial growth factor (P < .01). These changes did not differ between nulligravidas, women with previous preeclampsia, and women with a previous uncomplicated pregnancy. Post-heparin sFLT1 in nonpregnant women was higher than sFLT1 in uncomplicated pregnancy, but lower than sFLT1 in preeclampsia. Baseline and post-heparin sFLT1 were positively correlated (r(2) = 0.19; P < .01). Heparin increased the concentration of the 100-kDa sFLT1 isoform. Adding heparin to whole blood or plasma did not increase sFLT1. CONCLUSIONS: Nonpregnant women have a significant vascular store of releasable sFLT1. The size of this store does not differ between women with previous preeclampsia vs women with previous uncomplicated pregnancy.
CONTEXT: Research examining the source of excess soluble fms-like tyrosine kinase 1 (sFLT1) in preeclampsia has focused on the placenta. The potential contribution of the releasable store of sFLT1 in the systemic vasculature is unknown. OBJECTIVE: We asked whether the nonplacental releasable store of sFLT1 is larger in women with previous preeclampsia than in women with a previous uncomplicated pregnancy. DESIGN: We administered heparin to nulligravid women and to women with previous preeclampsia or a previous uncomplicated pregnancy. We compared post-heparin sFLT1 concentrations with those observed in uncomplicated pregnancy and preeclampsia. SETTING: The study was performed at Magee-Womens Hospital. PATIENTS: Participants included nulligravidas (n = 8), women 6-24 months postpartum (previous uncomplicated pregnancy, n = 16; previous preeclampsia, n = 15), and pregnant women (uncomplicated pregnancy, n = 30; preeclampsia, n = 25). INTERVENTION: Nonpregnant women received an unfractionated heparin bolus. MAIN OUTCOME MEASURES: Pre- and post-heparin plasma sFLT1, placental growth factor, and vascular endothelial growth factor were measured. RESULTS: In nonpregnant women, heparin increased plasma sFLT1 by 250-fold (P < .01), increased placental growth factor by 7-fold (P < .01), and decreased free vascular endothelial growth factor (P < .01). These changes did not differ between nulligravidas, women with previous preeclampsia, and women with a previous uncomplicated pregnancy. Post-heparin sFLT1 in nonpregnant women was higher than sFLT1 in uncomplicated pregnancy, but lower than sFLT1 in preeclampsia. Baseline and post-heparin sFLT1 were positively correlated (r(2) = 0.19; P < .01). Heparin increased the concentration of the 100-kDa sFLT1 isoform. Adding heparin to whole blood or plasma did not increase sFLT1. CONCLUSIONS: Nonpregnant women have a significant vascular store of releasable sFLT1. The size of this store does not differ between women with previous preeclampsia vs women with previous uncomplicated pregnancy.
Authors: Muna Noori; Ann E Donald; Aspasia Angelakopoulou; Aroon D Hingorani; David J Williams Journal: Circulation Date: 2010-07-19 Impact factor: 29.690
Authors: Sietze Reitsma; Dick W Slaaf; Hans Vink; Marc A M J van Zandvoort; Mirjam G A oude Egbrink Journal: Pflugers Arch Date: 2007-01-26 Impact factor: 3.657
Authors: Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand Journal: J Am Soc Nephrol Date: 2009-07-16 Impact factor: 10.121
Authors: Eiji Shibata; Augustine Rajakumar; Robert W Powers; Robert W Larkin; Carol Gilmour; Lisa M Bodnar; William R Crombleholme; Roberta B Ness; James M Roberts; Carl A Hubel Journal: J Clin Endocrinol Metab Date: 2005-05-10 Impact factor: 5.958
Authors: Robin E Gandley; Jennifer Rohland; Yan Zhou; Eiji Shibata; Gail F Harger; Augustine Rajakumar; Valerian E Kagan; Nina Markovic; Carl A Hubel Journal: Hypertension Date: 2008-06-30 Impact factor: 10.190
Authors: A Rajakumar; R W Powers; C A Hubel; E Shibata; F von Versen-Höynck; D Plymire; A Jeyabalan Journal: Placenta Date: 2008-11-17 Impact factor: 3.481
Authors: Tracey L Weissgerber; Andrea McConico; Bruce E Knudsen; Kim A Butters; Suzanne R Hayman; Wendy M White; Natasa Milic; Virginia M Miller; Vesna D Garovic Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-03-12 Impact factor: 3.619
Authors: Robin E Gandley; Andrew Althouse; Arundhathi Jeyabalan; Julia M Bregand-White; Stacy McGonigal; Ashley C Myerski; Marcia Gallaher; Robert W Powers; Carl A Hubel Journal: PLoS One Date: 2016-06-14 Impact factor: 3.240